Daniel Hutchins

Associate
Full contact info

Experience

IGM Biosciences – $201 Million IPO

September 18, 2019

Cooley advised underwriters on IGM Biosciences’ $201.3 million initial public offering of 12,578,125 shares of common stock, including full exercise of the underwriters’ option to purchase additional shares. Jefferies, Piper Jaffray, Stifel, Nicolaus & Company and Guggenheim Securities acted as joint book-running managers for the offering. IGM Biosciences’ securities now trade on the Nasdaq Global Select Market under the symbol “IGMS.” Partners Jonie Kondracki, Charlie Kim, Dave Peinsipp and Will Cai led the Cooley team.

Related contacts

Jonie Ing Kondracki
Partner, San Francisco
Charlie Kim
Partner, San Diego
David Peinsipp
Partner, San Francisco
Will Cai
Partner, Hong Kong
Natalie Karam
Partner, Palo Alto
Daniel Hutchins
Associate, Palo Alto

Related Practices & Industries

Atreca - $125 Million IPO

June 20, 2019

Cooley advised Atreca on its $125 million initial public offering of 7,350,000 shares of common stock. Atreca, whose securities now trade on the Nasdaq Global Select Market under the symbol “BCEL,” is a biopharmaceutical company using a differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. Partners Barbara Kosacz, Danielle Naftulin and Mike Tenta led the Cooley team.

Related contacts

Barbara Kosacz
Senior Counsel, Palo Alto
Danielle Naftulin
Partner, Palo Alto
William Beom Hong
Associate, Palo Alto
Daniel Hutchins
Associate, Palo Alto

Related Practices & Industries

AbCellera Biologics - $556 million IPO

Cooley advised the underwriters on AbCellera Biologic’s $556 million initial public offering of 27,772,500 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. Credit Suisse Securities (USA) LLC, Stifel, Nicolaus & Company, Incorporated, Berenberg Capital Markets LLC, SVB Leerink LLC and BMO Capital Markets Corp. acted as the joint book-running managers for the offering. AbCellera Biologics, whose securities now trade on the Nasdaq Global Market under the symbol “ABCL,” is a technology company that aims to become the centralized operating system for next-generation antibody discovery. Partners Charlie Kim, Kristin VanderPas, Div Gupta and Rich Segal led the Cooley team.

Related contacts

Charlie Kim
Partner, San Diego
Kristin VanderPas
Partner, San Francisco
Div Gupta
Partner, New York
Richard Segal
Partner, New York
Denny Won
Partner, San Francisco
Daniel Hutchins
Associate, Palo Alto

Related Practices & Industries

Admissions & credentials

California

State of Washington

US Patent and Trademark Office

Memberships & affiliations

Seattle IP American Inn of Court

Washington State Patent Law Association